Bone fractures and hypoglycemic treatment in type 2 diabetic patients: A case-control study

Diabetes Care

Volumn 31, Issue 2, 2008, Pages 199-203

  Monami, Matteo ^a   Cresci, Barbara ^a   Colombini, Angela ^a   Pala, Laura ^a   Balzi, Daniela ^b   Gori, Francesca ^a   Chiasserini, Veronica ^a   Marchionni, Niccolò ^a   Rotella, Carlo Maria ^a   Mannucci, Edoardo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Local Health Unit 10   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PHENFORMIN; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BODY MASS; BONE METABOLISM; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG MECHANISM; FEMALE; FOLLOW UP; FRACTURE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULINEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SMOKING;

AGED; BLOOD PRESSURE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; REFERENCE VALUES; TIME FACTORS;

EID: 38949182323     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-1736     Document Type: Article

References (26)

1. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920-925, 1999
2. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001
3. Vogt MT, Rubin D, Valentin RS, Palermo L, Donaldson WF III, Nevitt M, Cauley JA: Lumbar olisthesis and lower back symptoms in elderly white women: the Study of Osteoporotic Fractures. Spine 23:2640-2647, 1998
4. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38, 2001
5. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabete Metab Res Rev 20:196-204, 2004
6. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404-3410, 2006
7. de Liefde I, van der KM, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720, 2005
8. Lipscombe LL, Jamal SA, Booth GL, Hawker GA: The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 30:835-841, 2007
9. Janghorbani M, Feskanich D, Willett WC, Hu F: Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 29:1573-1578, 2006
10. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005
11. van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, Birkenhager JC, Pols HA: Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam Study. Ann Intern Med 122:409-414, 1995
12. Tuominen JT, Impivaara O, Puukka P, Ronnemaa T: Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196-1200, 1999
13. Lunt M, Masaryk P, Scheidt-Nave C, Nijs J, Poor G, Pols H, Falch JA, Hammermeister G, Reid DM, Benevolenskaya L, Weber K, Cannata J, O'Neill TW, Felsenberg D, Silman AJ, Reeve J: The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study. Osteoporos Int 12:688-698, 2001
14. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J: Biphasic fracture risk in diabetes: a population-based study. Bone 40:1595-1601, 2007
15. Vestergaard P, Rejnmark L, Mosekilde L: Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-1299, 2005
16. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR: Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354, 2006
17. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR: The peroxisome proliferator-activated receptorgamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310, 2007
18. Yaturu S, Bryant B, Jain SK: Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30:1574-1576, 2007
19. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
20. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406, 2004
21. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC: Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216, 2004
22. Thrailkill KM, Lumpkin CK, Jr, Bunn RC, Kemp SF, Fowlkes JL: Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 289:E735-E745, 2005
23. World Health Organization: Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. Geneva, World Health Org., 2000 (Tech Rep Ser, no. 894)
24. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers A, Ni MC, Clark T: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension: guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21:1009-1060, 1999
25. Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994
26. Schwartz AV, Sellmeyer DE: Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 30:1670-1671, 2007